← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 DELISTED Centogene N.V. Common Shares CNTG	–	–	–	–
102	102 Coya Therapeutics COYA $102M	–	–	–	–
103	103 Caribou Biosciences CRBU $49.8M	–	–	–	–
104	104 DELISTED CARGO Therapeutics CRGX	–	–	–	–
105	105 CRISPR Therapeutics CRSP $4.98B	–	–	–	–
106	DBTX 106 DELISTED Decibel Therapeutics, Inc. Common Stock DBTX	–	–	–	–
107	107 DELISTED DermTech, Inc. Common Stock DMTK	–	–	–	–
108	108 Ginkgo Bioworks DNA $792M	–	–	–	–
109	109 Design Therapeutics DSGN $656M	–	–	–	–
110	110 Precision BioSciences DTIL $170M	–	–	–	–
111	111 enGene Therapeutics ENGN $115M	–	–	–	–
112	112 Estrella Immunopharma ESLA $23.3M	–	–	–	–
113	113 FibroBiologics FBLG $7.08M	–	–	–	–
114	114 4D Molecular Therapeutics FDMT $711M	–	–	–	–
115	FRLN 115 DELISTED Freeline Therapeutics Holdings plc American Depositary Shares FRLN	–	–	–	–
116	116 DELISTED Generation Bio GBIO	–	–	–	–
117	117 CytoMed Therapeutics GDTC $10.4M	–	–	–	–
118	118 Guardant Health GH $22.3B	–	–	–	–
119	GMDA 119 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	–	–	–	–
120	120 Corgi Genomics & Precision Medicine ETF GNMX $1.68M	–	–	–	–
121	121 Global X Genomics & Biotechnology ETF GNOM $99.5M	–	–	–	–
122	122 Genprex GNPX $1.88M	–	–	–	–
123	123 Genenta Science GNTA $32.3M	–	–	–	–
124	124 GRAIL Inc GRAL $6.05B	–	–	–	–
125	GRCL 125 DELISTED Gracell Biotechnologies Inc. American Depositary Shares GRCL	–	–	–	–